ByteDance is spinning out its artificial intelligence drug discovery unit into an independent entity, marking the tech giant’s first major attempt to commercialize its “AI for Science” (AI4S) research. The new company, operating under the platform name Anew Labs, has begun raising independent financing, though ByteDance will retain a controlling stake, according to a report by 36Kr and KR Asia.
The strategic restructuring will see the unit’s team, algorithms, technology platform, and existing pipeline assets transferred to the new entity. However, Anew Labs will continue to receive critical computing power support from Volcano Engine, ByteDance’s enterprise cloud services division.
Consolidating AI4S Talent
The drug discovery unit was originally founded in 2021 and is led by Kai Liu. It currently consists of approximately 50 core members, blending AI4S talent and algorithm specialists with pharmaceutical industry experts. As part of the spinout, ByteDance’s protein structure prediction team, which previously operated separately, has been folded into Anew Labs, consolidating the company’s computational biology expertise under one roof.
The team has already produced significant technical outputs. In 2025, they released Protenix and Seedfold, followed by Protenix-v1 and Protenix-v2 in 2026. These tools provide open-source structure prediction for proteins and ligands. The unit has also developed protein design tools, such as PXDesign, for designing protein binders.
The Anew Labs platform is designed to handle the complex, multi-stage process of real-world drug development. Its research capabilities span several critical areas, including AnewSampling for protein-ligand dynamic structure prediction, AnewOmni for all-atom molecule generation, AnewFEP for free energy calculation, AnewSynth for synthetic feasibility prediction, and scNext for virtual cell modeling.
Early Clinical Validation
The unit’s theoretical work is already translating into tangible pharmaceutical progress. In April 2026, Anew Labs disclosed an IL-17 small-molecule program at the American Association of Immunologists annual meeting. This marked the first reported case globally of using small molecules to successfully block three IL-17 family dimers. The IL-17 pathway is a critical target in treating autoimmune diseases such as psoriasis and ankylosing spondylitis, demonstrating the commercial and medical viability of Anew Labs’ AI-driven approach.
The decision to spin out the unit now reflects both the technology’s maturation and the immense market opportunity. According to IQVIA, global spending on medicines is expected to reach approximately $2.3 trillion by 2028.
The Logic of Independence
The spinout strategy is intended to solve several structural challenges inherent in housing a highly specialized scientific unit within a consumer internet company. By operating independently, Anew Labs aims to attract top-tier pharmaceutical and biotech talent who might be hesitant to join a social media conglomerate. Furthermore, independence will enable more agile decision-making tailored to the lengthy and highly regulated drug development cycle, rather than the rapid iteration cycles typical of ByteDance’s core app business.
The move also aligns with broader industry trends, as tech giants increasingly seek to monetize their massive investments in AI infrastructure by applying them to high-value scientific domains. With Anew Labs, ByteDance is signaling that its ambitions extend far beyond short-form video and enterprise software, positioning itself as a serious contender in the lucrative and rapidly evolving field of AI-accelerated biotechnology.
The AI4S Commercialization Challenge
The broader AI for Science movement in China faces a fundamental tension between the long timelines of scientific discovery and the short-term revenue expectations of technology investors. Drug discovery, in particular, is notorious for its high failure rates and decade-long development cycles. Even with AI dramatically accelerating the early stages of the process, clinical trials and regulatory approval remain time-consuming and expensive.
By spinning out Anew Labs as an independent entity, ByteDance is effectively separating the long-term, high-risk bet on pharmaceutical AI from its core advertising and entertainment business. This structure allows the spinout to pursue a dedicated fundraising strategy, attracting specialized life sciences investors who are accustomed to the longer investment horizons required in the pharmaceutical sector.
The move also reflects a growing recognition within China’s tech sector that AI4S applications require fundamentally different organizational structures and incentive systems than consumer internet products. The pace of scientific discovery cannot be measured in quarterly earnings reports, and the talent required, researchers with deep expertise in both machine learning and domain-specific sciences, demands a culture and compensation structure distinct from that of a typical tech company.
As Anew Labs begins its independent journey, it joins a growing cohort of specialized AI drug-discovery startups in China, including Insilico Medicine and XtalPi, that are seeking to translate the country’s AI capabilities into tangible breakthroughs in human health. The success or failure of these ventures will be a critical indicator of whether China’s AI4S ambitions can deliver real-world impact beyond the benchmark leaderboards.